Entasis Therapeutics Holdings Inc. (ETTX:NASDAQ) Annual Reports & Investor Relations Material

Overview

Entasis is a biopharmaceutical company dedicated to developing innovative antibacterial products that treat severe infections caused by multiplex-resistant Gram-negative bacteria. Their platform focuses on targeting specific pathogens, yielding a strong pipeline of product candidates such as sulbactam-durlobactam for Acinetobacter baumannii infection, zoliflodacin for Neisseria gonorrhoeae infection, ETX0282CPDP for Enterobacteriaceae infection, and ETX0462 for Pseudomonas infection. The company is currently in a clinical stage, with a mission to commercialize potentially life-saving treatments.

Annual Reports

Frequently Asked Questions

What is Entasis Therapeutics Holdings Inc.'s ticker?

Entasis Therapeutics Holdings Inc.'s ticker is ETTX

What exchange is Entasis Therapeutics Holdings Inc. traded on?

The company's shares trade on the NASDAQ stock exchange

Where are Entasis Therapeutics Holdings Inc.'s headquarters?

They are based in Waltham, Massachusetts

How many employees does Entasis Therapeutics Holdings Inc. have?

There are 11-50 employees working at Entasis Therapeutics Holdings Inc.

What is Entasis Therapeutics Holdings Inc.'s website?

It is https://www.entasistx.com/

What type of sector is Entasis Therapeutics Holdings Inc.?

Entasis Therapeutics Holdings Inc. is in the Healthcare sector

What type of industry is Entasis Therapeutics Holdings Inc.?

Entasis Therapeutics Holdings Inc. is in the Biotechnology industry

Who are Entasis Therapeutics Holdings Inc.'s peers and competitors?

The following five companies are Entasis Therapeutics Holdings Inc.'s industry peers:

- Dicerna Pharmaceuticals

- CASI Pharmaceuticals Inc

- OptiBiotix Health Plc

- SIGA

- AorTech International plc